From Wikipedia, the free encyclopedia
Jump to: navigation, search
Lacidipine structure.svg
Clinical data
Trade names Lacipil, Motens
AHFS/ International Drug Names
Routes of
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability ~10%
Protein binding >95%
Metabolism Hepatic
Onset of action 30–50 min
Biological half-life 13–19 hours
Excretion Feces (~70%)
CAS Number
PubChem CID
ECHA InfoCard 100.166.373
Chemical and physical data
Formula C26H33NO6
Molar mass 455.543 g/mol
3D model (Jmol)

Lacidipine (tradenames Lacipil (GSK) or Motens (Boehringer Ingelheim)) is a calcium channel blocker. It is available as tablets containing 2 or 4 mg.


Lacidipine synthesis: C. Semeraro et al., DE 3529997 ; eidem, U.S. Patent 4,801,599 (1986, 1989 both to Glaxo).

The synthesis starts with the Wittig reaction of phthalaldehyde (1) with the ylide from triphenylphosphonium salt (2). The trans stereochemistry of the product (3) follows from the fact that the rxn is not carried out under salt-free conditions; selectivity for monoalkylation is probably due to steric hindrance from the newly introduced adjacent side chain to the adjacent formyl group. reaction of tat intermediate with ethyl acetoacetate and ammonia gives the dihydropyridine lacidipine (5).


Teludipine synthesis: Claudio Semeraro, et al. U.S. Patent 5,162,345 (1992 to Glaxo).

Further modification of this compound depends on the allylic nature of the ring methyl groups. Thus reaction of 5 with pyridinium perbromide leads to the bromination of one groups and the formation of 6. The displacement of halogen by dimethylamine leads to the tertiary amine teludipine (7).

External links[edit]